Literature DB >> 19398662

Cardiac mast cells mediate left ventricular fibrosis in the hypertensive rat heart.

Scott P Levick1, Jennifer L McLarty, David B Murray, Rebecca M Freeman, Wayne E Carver, Gregory L Brower.   

Abstract

Correlative data suggest that cardiac mast cells are a component of the inflammatory response that is important to hypertension-induced adverse myocardial remodeling. However, a causal relationship has not been established. We hypothesized that adverse myocardial remodeling would be inhibited by preventing the release of mast cell products that may interact with fibroblasts and other inflammatory cells. Eight-week-old male spontaneously hypertensive rats were treated for 12 weeks with the mast cell stabilizing compound nedocromil (30 mg/kg per day). Age-matched Wistar-Kyoto rats served as controls. Nedocromil prevented left ventricular fibrosis in the spontaneously hypertensive rat independent of hypertrophy and blood pressure, despite cardiac mast cell density being elevated. The mast cell protease tryptase was elevated in the spontaneously hypertensive rat myocardium and was normalized by nedocromil. Treatment of isolated adult spontaneously hypertensive rat cardiac fibroblasts with tryptase induced collagen synthesis and proliferation, suggesting this as a possible mechanism of mast cell-mediated fibrosis. In addition, nedocromil prevented macrophage infiltration into the ventricle. The inflammatory cytokines interferon-gamma and interleukin (IL)-4 were increased in the spontaneously hypertensive rat and normalized by nedocromil, whereas IL-6 and IL-10 were decreased in the spontaneously hypertensive rat, with nedocromil treatment normalizing IL-6 and increasing IL-10 above the control. These results demonstrate for the first time a causal relationship between mast cell activation and fibrosis in the hypertensive heart. Furthermore, these results identify several mechanisms, including tryptase, inflammatory cell recruitment, and cytokine regulation, by which mast cells may mediate hypertension-induced left ventricular fibrosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19398662     DOI: 10.1161/HYPERTENSIONAHA.108.123158

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  66 in total

Review 1.  Cardiac mast cells: the centrepiece in adverse myocardial remodelling.

Authors:  Scott P Levick; Giselle C Meléndez; Eric Plante; Jennifer L McLarty; Gregory L Brower; Joseph S Janicki
Journal:  Cardiovasc Res       Date:  2010-08-24       Impact factor: 10.787

Review 2.  Mechanisms of fibrosis: therapeutic translation for fibrotic disease.

Authors:  Thomas A Wynn; Thirumalai R Ramalingam
Journal:  Nat Med       Date:  2012-07-06       Impact factor: 53.440

Review 3.  Mast cells and metabolic syndrome.

Authors:  Jie Zhang; Guo-Ping Shi
Journal:  Biochim Biophys Acta       Date:  2010-12-23

Review 4.  Mechanisms of Cardiac Repair and Regeneration.

Authors:  Kathleen M Broughton; Bingyan J Wang; Fareheh Firouzi; Farid Khalafalla; Stefanie Dimmeler; Francisco Fernandez-Aviles; Mark A Sussman
Journal:  Circ Res       Date:  2018-04-13       Impact factor: 17.367

5.  Efficacy of antihistamines on mortality in patients receiving maintenance hemodialysis: an observational study using propensity score matching.

Authors:  Kiyotsugu Omae; Masao Yoshikawa; Hiroshi Sakura; Kosaku Nitta; Tetsuya Ogawa
Journal:  Heart Vessels       Date:  2017-05-16       Impact factor: 2.037

6.  Tryptase/Protease-activated receptor 2 interactions induce selective mitogen-activated protein kinase signaling and collagen synthesis by cardiac fibroblasts.

Authors:  Jennifer L McLarty; Giselle C Meléndez; Gregory L Brower; Joseph S Janicki; Scott P Levick
Journal:  Hypertension       Date:  2011-07-05       Impact factor: 10.190

7.  Mast cell-deficiency protects mice from streptozotocin-induced diabetic cardiomyopathy.

Authors:  Aina He; Wenqian Fang; Kun Zhao; Yajun Wang; Jie Li; Chongzhe Yang; Feriel Benadjaoud; Guo-Ping Shi
Journal:  Transl Res       Date:  2019-01-19       Impact factor: 7.012

Review 8.  Substance P in heart failure: the good and the bad.

Authors:  Heather M Dehlin; Scott P Levick
Journal:  Int J Cardiol       Date:  2013-11-12       Impact factor: 4.164

Review 9.  Chymase inhibitors for the treatment of cardiac diseases: a patent review (2010-2018).

Authors:  Sarfaraz Ahmad; Carlos M Ferrario
Journal:  Expert Opin Ther Pat       Date:  2018-10-10       Impact factor: 6.674

Review 10.  Could interferon-gamma be a therapeutic target for treating heart failure?

Authors:  Scott P Levick; Paul H Goldspink
Journal:  Heart Fail Rev       Date:  2014-03       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.